Lumiracoxib

• CAT Number: R009200
• CAS Number: 220991-20-8
• Molecular Formula: C15H13ClFNO2
• Molecular Weight: 293.722
• Purity: ≥95%
• Synonyms: 2-[(2-Chloro-6-fluorophenyl)amino]-5-methylbenzeneacetic Acid; ?2-[2-(2-Chloro-6-fluorophenylamino)-5-methylphenyl]acetic Acid; CGS 35189; COX 189; Prexige
• Target: COX
• Solubility: Soluble in DMSO > 10 mM
• Storage: Store at -20°C
• IUPAC Name: 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
• InChI: InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
• InChIKey: KHPKQFYUPIUARC-UHFFFAOYSA-N
• SMILES: CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O

Lumiracoxib is a selective COX-2 inhibitor used primarily as an anti-inflammatory and analgesic agent. It is part of the class of nonsteroidal anti-inflammatory drugs (NSAIDs) that specifically targets the cyclooxygenase-2 enzyme, reducing the production of prostaglandins responsible for inflammation and pain. Lumiracoxib was used in the treatment of osteoarthritis, rheumatoid arthritis, and acute pain, though its use has been limited due to concerns over hepatotoxicity. Its structure allows for selective inhibition of COX-2, minimizing gastrointestinal side effects commonly seen with traditional NSAIDs.